Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preperations

British Journal of Clinical Pharmacology

Volumn 47, Issue 3, 1999, Pages 291-298

  Prueksaritanont, Thomayant ^a   Ma, Bennett ^a   Tang, Cuyue ^a   Meng, Yuan ^a   Assang, Carol ^a   Lu, Ping ^a   Reider, Paul J ^a   Lin, Jiunn H ^a   Baillie, Thomas A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

CYP3A; Drug interactions; HMG CoA reductase inhibitor; In vitro metabolism; Mibefradil; Statins

Indexed keywords

ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; MIBEFRADIL; SIMVASTATIN;

ARTICLE; DRUG METABOLISM; HUMAN; HUMAN TISSUE; LIVER METABOLISM; LIVER MICROSOME; PRIORITY JOURNAL;

ARYL HYDROCARBON HYDROXYLASES; BENZIMIDAZOLES; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FATTY ACIDS, MONOUNSATURATED; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; KETOCONAZOLE; KINETICS; LOVASTATIN; MIBEFRADIL; MICROSOMES, LIVER; OXIDOREDUCTASES, N-DEMETHYLATING; PYRIDINES; PYRROLES; SIMVASTATIN; TETRAHYDRONAPHTHALENES;

EID: 0033026601     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00903.x     Document Type: Article

References (21)

1. 1 Pedersen TR, Berg K, Cook TJ, et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1996; 156: 2085-2092.
2. 2 Clozel J-P, Osterricder W, Kleinbloesem CH, et al. Ro 40-5967: a new non-dihydropyridine calcium antagonist. Cardiovasc Drug Rev 1991; 9: 4-17.
3. 3 Roche FDA announce new drug-interaction warnings for mibefradil. Am J Health-Syst Pharm 1998; 55: 210.
4. 4 Prucksaritanont T, Gorham LM, Ma B, et al. In vitro metabolism of simvastatin in humans: Identification of metabolizing enzymes and effects of the drug on hepatic P-450s. Drug Metab Dispos 1997; 25: 1191-1199.
5. 5 Wang RW, Kari PH, Lu AHY, Thomas PE, Guengerich PF, Vyas KP. Biotransformation of lovastatin: IV. Identification of cytochrome P-450, 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch Biochem Biophys 1991 290: 355-361.
6. 6 Yang BB, Siedlik PH, Smithers JA, Sedman AJ, Stern RH. Atorvastatin pharmacokinetic interactions with other CYP3A4 substrates: crythromycin and ethinyl estradiol. Pharm Res 1996; 13 (9(Suppl): S437.
7. 7 Boberg M, Angerbauer R, Fey P, et al. Metabolism of cerivastatin by human liver microsomes in vitro: Characterization of primary metabolic pathways and cytochrome P450 isozymes involved. Drug Metab Dispos 1997; 25: 321-331.
8. 8 Transon C, Leemann T, Dayer P. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1996; 50: 209-215.
9. 9 Wrighton SA, Ring BJ. Inhibition of human CYP3A catalyzed 1′-hydroxy midazolam formation by ketoconazole, nifedipine, crythromycin, cimetidine, and nizatidine. Pharm Res 1994; 11: 921-924.
10. 10 von Moltke LL, Greenblatt DJ, Schmider J, et al. Midazolam hydroxylation by human liver microsomes in vitro: Inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J Clin Pharmacol 1996; 36: 783-791.
11. 11 Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994; 55: 481-485.
12. 12 Prueksaritanont T, Gorham LM, Hochman J, Tran L, Vyas KP. Comparative studies of drug metabolizing enzymes in dog, monkey and human small intestines and in Caco-2 cells. Drug Metab Dispos 1996; 24: 634-642.
13. 13 Newton DJ, Wang RW, Lu AHY. Cytochrome P450 inhibitors: Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 1995; 23: 154-158.
14. 14 Silverman RB. Mechanism-Based Enzyme Inactivation: Chemistry and Enzymology, Vol 1, Boca Raton, FL. CRC Press, 1988: 3-15.
15. 15 Parke-Davis. Lipitor (Atorvastatin calcium): Physicians' Desk Reference, Montvale, NJ. Medical Economics Co. 1998: 2186-2189.
16. 16 Dain JC, Fu E, Gorski J, Nicoletti J, Scallen TJ. Biotransformation of fluvastatin sodium in humans. Drug Metab Dispos 1993; 21: 567-572.
17. 17 Chiba M, Nishime JA, Lin JH. Potent and selective inactivation of human liver microsomal cytochrome P-450 isoforms by L-754,394, an investigational human immune deficiency virus protease inhibitor. J Pharmacol Exp Ther 1995; 275: 1527-1534.
18. 18 Wiltshire HR, Sutton BM, Heeps G, et al. Metabolism of the calcium antagonist, mibefradil (POSICOR™, Ro 40-5967). Part III. Comparative pharmacokinetics of mibefradil and its major metabolites in rats, marmoset, cynomolgus monkey and man. Xenobiotica 1997; 27: 557-571.
19. 19 Murray M, Reidy GF. Selectivity in the inhibition of mammalian cytochromes P-450 by chemical agents. Pharmacol Rev 1990; 42: 85-101.
20. 20 Amsden GW. Macrolides versus azalides: a drug interaction update. Ann Pharmacother 1995; 29: 906-917.
21. 21 Ochmann K, Mueck W, Unger S, Kuhlmann J. Influence of erythromycin pre-and co-treatment on the single-dose pharmacokinetics of cerivastatin. Eur J Clin Pharmacol 1997; 52(Suppl): A139.